Research programme: diabetes therapy - Oxford BioMedica
Alternative Names: Diabetes therapy research programme - Oxford BioMedicaLatest Information Update: 13 Aug 2003
Price :
$50 *
At a glance
- Originator Oxford BioMedica
- Class Cell therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 13 Aug 2003 Discontinued - Preclinical for Type-1 diabetes mellitus (unspecified route)
- 19 May 2003 No development reported - Preclinical for Type-1 diabetes mellitus (unspecified route)
- 05 Oct 2001 Oxford BioMedica and Modex Therapeutics terminated their collaboration on diabetes